Showing 601 - 620 results of 1,420 for search '"arthritis"', query time: 0.08s Refine Results
  1. 601
  2. 602
  3. 603
  4. 604
  5. 605

    Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt

    Published 2020-10-01
    “…Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA.Methods Data were pooled for patients with RA who received ≥1 tofacitinib dose. …”
    Get full text
    Article
  6. 606

    Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison by Ulf Lindström, Johan Askling, Katerina Chatzidionysiou, Lotta Ljung, Lars Klareskog, Martin Neovius, Nils Feltelius, Eva Baecklund, Christopher Sjöwall, Helena Forsblad-d’Elia, Carl Turesson, Elisabet Lindqvist, Thomas Frisell, Alf Kastbom, Helena Forsblad-d'Elia, Jonas Söderling, Ann Knight, Gerd-Marie Alenius, Gustaf Magnus Bruze

    Published 2025-01-01
    “…Objective To compare work loss after starting tumour necrosis factor inhibitors (TNFi), rituximab, abatacept or tocilizumab in patients with rheumatoid arthritis (RA).Methods We used data from the Swedish Rheumatology Quality Register to identify patients aged 19-62 years who were treated with TNFi (n=15 093), rituximab (n=2123), abatacept (n=1877) or tocilizumab (n=1720) between 2007 and 2020. …”
    Get full text
    Article
  7. 607
  8. 608

    Tumor Necrosis Factor Receptor 1 Is Required for Human Umbilical Cord–Derived Mesenchymal Stem Cell–Mediated Rheumatoid Arthritis Therapy by Guangyang Liu, Herui Wang, Chenliang Zhang, Xin Li, Yi Mi, Yaoyao Chen, Liqiang Xu, Li Miao, Haomiao Long, Yongjun Liu

    Published 2025-01-01
    “…Rheumatoid arthritis (RA) is a systemic, chronic inflammatory disease characterized by altered levels of inflammatory cytokines. …”
    Get full text
    Article
  9. 609

    Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis by Kurt de Vlam, Rik Lories, M Van Mechelen, Sofia Pazmino, P Verschueren, Barbara Neerinckx, Lies Storms, Alla Ishchenko

    Published 2025-01-01
    “…Objectives To investigate serum lipid profile in early, treatment-naïve psoriatic arthritis (PsA) and to determine whether changes in classical lipids or apolipoproteins are specific to PsA.Methods Total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-c), low-density lipoprotein cholesterol (LDL-c), HDL-c, triglycerides, apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1) were compared in newly diagnosed untreated PsA patients (n=75) to sex- and age-matched controls (healthy control (HC)) (n=61) and early untreated rheumatoid arthritis (RA) patients (n=50).Results Among classical lipid measurements, HDL-c levels were lower in PsA than in HC and RA (df 2, χ210, p=0.006, PsA vs HC p=0.013). …”
    Get full text
    Article
  10. 610

    Diagnostic Dilemma of Disseminated Histoplasmosis Mimicking Hemophagocytosis Lymphohistiocytosis in Patient with Rheumatoid Arthritis on Anti-TNF Therapy: Case Report and Review of the Literature by Saurav Suman, Aleksander Lenert

    Published 2019-01-01
    “…Tumor necrosis factor inhibitors (TNFi) have become the cornerstone for the treatment of rheumatoid arthritis and other systemic autoimmune conditions. …”
    Get full text
    Article
  11. 611

    Patellar Tendon Properties and Lower Limb Function in Rheumatoid Arthritis and Ankylosing Spondylitis versus Healthy Controls: A Cross-Sectional Study by Verena Matschke, Jeremy G. Jones, Andrew B. Lemmey, Peter J. Maddison, Jeanette M. Thom

    Published 2013-01-01
    “…Objective. Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) lead to inflammation in tendons and peritendinous tissues, but effects on biomechanical tendon function are unknown. …”
    Get full text
    Article
  12. 612
  13. 613
  14. 614
  15. 615

    Lipid Peroxidation-Mediated Inflammation Promotes Cell Apoptosis through Activation of NF-κB Pathway in Rheumatoid Arthritis Synovial Cells by Geng Yin, Ying Wang, Xiao-min Cen, Min Yang, Yan Liang, Qi-bing Xie

    Published 2015-01-01
    “…Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of multiple joints. …”
    Get full text
    Article
  16. 616
  17. 617
  18. 618

    Active Ingredients and Potential Mechanism of Additive Sishen Decoction in Treating Rheumatoid Arthritis with Network Pharmacology and Molecular Dynamics Simulation and Experimental Verification by Ren J, Liu Z, Qi X, Meng X, Guo L, Yu Y, Dong T, Li Q

    Published 2025-01-01
    “…Jinhong Ren, Ze Liu, Xiaoming Qi, Xiangda Meng, Linglin Guo, Yating Yu, Tao Dong, Qingshan Li Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, College of Traditional Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine, Jinzhong, People’s Republic of ChinaCorrespondence: Qingshan Li, Email sxlqs0501@sxtcm.edu.cnBackground: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which macrophages produce cytokines that enhance inflammation and contribute to the destruction of cartilage and bone. …”
    Get full text
    Article
  19. 619

    Application of Surface Roughness Analysis on Micro–Computed Tomographic Images of Bone Erosion: Examples Using a Rodent Model of Rheumatoid Arthritis by Matthew D. Silva, Jason Ruan, Elizabeth Siebert, Anneli Savinainen, Bruce Jaffee, Lisa Schopf, Sudeep Chandra

    Published 2006-10-01
    “…Quantifying the bone erosion in preclinical models of rheumatoid arthritis is valuable for the evaluation of drug treatments. …”
    Get full text
    Article
  20. 620

    Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis by Mahmood M. T. M. Ally, Bridget Hodkinson, Pieter W. A. Meyer, Eustasius Musenge, Mohammed Tikly, Ronald Anderson

    Published 2013-01-01
    “…Matrix metalloproteinase-3 (MMP-3) is involved in the immunopathogenesis of rheumatoid arthritis (RA), but little is known about its relationship to genetic susceptibility and biomarkers of disease activity, especially acute phase reactants in early RA. …”
    Get full text
    Article